Overview Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer Status: Completed Trial end date: 2011-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer. Phase: Phase 2 Details Lead Sponsor: Gyeongsang National University HospitalCollaborators: Chung-Ang University Hosptial, Chung-Ang University College of MedicineDong-A University HospitalTreatments: CisplatinErlotinib HydrochlorideGemcitabine